About Cardinor
Cardinor is a Healthcare company based in Oslo (Norway) founded in 2015. Biomarker-based assays for cardiovascular diseases are developed and provided. Cardinor has raised $921.84 thousand across 5 funding rounds from investors including European Union, IIG PLC and EIC Fund. The company has 2 employees. Cardinor offers products and services including Secretoneurin ELISA Assay. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, In-Vitro Diagnostics and Arrhythmia. Its legal entity is CardiNor AS.
Company details
Cardinor was founded in 2015 in Oslo, Norway, as a provider of biomarker-based assays targeting cardiovascular diseases. The assays utilize the neuropeptide secretoneurin, linked to cardiomyocyte calcium handling, to support identification of therapeutic strategies for heart disease patients. Operations focus on diagnostic applications, with the initial emphasis placed on arrhythmia testing within the biotechnology sector.
- Headquarters Oslo, Norway
- Employees 2
- SectorsHealthcare
- Website cardinor.com
- Legal Name Cardinor As
- Annual Revenue$359.64 K (USD)8as on Dec 31, 2021
- Net Profit$592.42 K (USD)598as on Dec 31, 2021
- EBITDA$592.63 K (USD)598as on Dec 31, 2021
- Total Equity Funding$921.84K (USD)
in 5 rounds
- Latest Funding Round$171.84K (USD), Seed
Mar 2021
- InvestorsEuropean Union
& 2 more
- Employee Count2
Products & Services of Cardinor
Cardinor offers a comprehensive portfolio of products and services, including Secretoneurin ELISA Assay.
Assay for measuring secretoneurin in heart failure patients
Funding Insights of Cardinor
Cardinor has successfully raised a total of $921.84K across 5 strategic funding rounds. The most recent funding activity was a Seed round of $171.84 thousand completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $921,842
- Total Rounds 5
- Last Round Seed — $171,842
- First Round $750,000
(Nov 2015)
- Investors Count 3
All 5 funding rounds of Cardinor with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $171,842 | Seed | – | IIG | – |
| Feb 2020 | $55,020 | Grant | – | – | |
| Dec 2019 | $133,273 | Grant | – | – | |
| Oct 2019 | $54,672 | Grant | – | – | |
| Nov 2015 | $750,000 | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in Cardinor
Cardinor has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, IIG PLC and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are directed by IIG toward life sciences startups. | 2020 | iigplc.com | London, United Kingdom | |
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Cardinor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Cardinor
3 dated milestones of Cardinor across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Cardinor is founded.
- Funding First funding round of $750K.
- Funding Latest funding round, Seed, of $172K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cardinor
Complete news archive for Cardinor
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cardinor
Cardinor was founded in 2015.
Cardinor is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Cardinor is a funded company, having raised a total of $921.84K across 5 funding rounds to date. The company's 1st funding round was a Seed of $750K, raised on Nov 2015.
Cardinor has 2 employees.
Annual revenue of Cardinor is $359.64K as on Dec 31, 2021.
Cardinor was founded in 2015 in Oslo, Norway, as a provider of biomarker-based assays targeting cardiovascular diseases. The assays utilize the neuropeptide secretoneurin, linked to cardiomyocyte calcium handling, to support identification of therapeutic strategies for heart disease patients. Operations focus on diagnostic applications, with the initial emphasis placed on arrhythmia testing within the biotechnology sector.
Cardinor offers Secretoneurin ELISA Assay.
Cardinor has 3 investors. Key investors include European Union, IIG PLC, and EIC Fund.
Cardinor operates through Cardinor As.